TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED Ratings Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Singapore S.E.
Equities
T14
CNE100000924
|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.98 USD | -0.50% |
|
-0.50% | -4.35% |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The group's high margin levels account for strong profits.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Weaknesses
- The company appears highly valued given the size of its balance sheet.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -4.35% | 3.04B | C | ||
| +38.08% | 6.05B | B- | ||
| -16.43% | 4.45B | C+ | ||
| -12.46% | 3.06B | B- | ||
| -0.59% | 2.58B | - | D+ | |
| +34.54% | 1.79B | - | ||
| +0.93% | 1.66B | - | - | |
| -10.63% | 1.63B | - | - | |
| -12.50% | 1.54B | C- | ||
| +37.15% | 1.42B | - |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
-
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 600329 Stock
- T14 Stock
- Ratings Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited
